Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer

Trinh Le Huy; My Hanh Bui; Toi Chu Dinh; Hoang Thi Hong Xuyen

doi:10.3889/oamjms.2019.368

Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer

Open Access Maced J Med Sci. 2019 Dec 10;7(24):4244-4249. doi: 10.3889/oamjms.2019.368. eCollection 2019 Dec 30.

Authors

Trinh Le Huy¹, My Hanh Bui^{2

3}, Toi Chu Dinh⁴, Hoang Thi Hong Xuyen⁵

Affiliations

¹ Department of Oncology, Hanoi Medical University Hospital, Hanoi, Vietnam.
² Tuberculosis and Lung Disease Department, Hanoi Medical University, Hanoi, Vietnam.
³ Scientific Research & International Cooperation Department, Hanoi Medical University Hospital, Hanoi, Vietnam.
⁴ Department of Human and Animal Physiology, Faculty of Biology, Hanoi National University of Education, Hanoi, Vietnam.
⁵ Center for Development of Curriculum and Human Resource in Health, Hanoi Medical University, Hanoi. Vietnam.

Abstract

Background: In recent times, scientists have found new treatments for colorectal cancer patients.

Aim: The study is to evaluate the efficacy and toxicity of triplet combination chemotherapy of 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for patients with metastatic colorectal cancer in stage IV.

Methods: Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients.

Results: The overall response rate of the treatment was 79.4%. The average progression-free survival was 13.4 ± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other adverse event was very low at percentage.

Conclusions: The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable.

Keywords: Efficacy; Folfoxiri; Metastatic colorectal cancer; Toxicity.